Astellas ends licensing deal with NeuroSearch
This article was originally published in Scrip
Executive Summary
Astellas has ended a licensing agreement with NeuroSearch for the global development of a novel dopaminergic stabilising agent for schizophrenia and other CNS disorders. The Danish firm's continuing in-house clinical programme for Huntingdon's disease is unaffected.